Matrix Capital Management Company’s Zentalis Pharmaceuticals ZNTL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $16.2M | Hold |
13,959,973
| – | – | 7.27% | 4 |
|
|
2025
Q1 | $22.2M | Hold |
13,959,973
| – | – | 6.39% | 4 |
|
|
2024
Q4 | $42.3M | Hold |
13,959,973
| – | – | 1.97% | 5 |
|
|
2024
Q3 | $51.4M | Hold |
13,959,973
| – | – | 2.45% | 5 |
|
|
2024
Q2 | $57.1M | Hold |
13,959,973
| – | – | 0.43% | 15 |
|
|
2024
Q1 | $220M | Hold |
13,959,973
| – | – | 2.04% | 11 |
|
|
2023
Q4 | $211M | Hold |
13,959,973
| – | – | 2.18% | 11 |
|
|
2023
Q3 | $280M | Hold |
13,959,973
| – | – | 3.36% | 11 |
|
|
2023
Q2 | $394M | Buy |
13,959,973
+4,760,000
| +52% | +$134M | 4.58% | 8 |
|
|
2023
Q1 | $158M | Hold |
9,199,973
| – | – | 2.15% | 10 |
|
|
2022
Q4 | $185M | Hold |
9,199,973
| – | – | 3.54% | 10 |
|
|
2022
Q3 | $199M | Hold |
9,199,973
| – | – | 3.81% | 11 |
|
|
2022
Q2 | $259M | Buy |
9,199,973
+4,850,694
| +112% | +$136M | 5.86% | 8 |
|
|
2022
Q1 | $201M | Hold |
4,349,279
| – | – | 2.41% | 15 |
|
|
2021
Q4 | $366M | Hold |
4,349,279
| – | – | 4.07% | 13 |
|
|
2021
Q3 | $290M | Buy |
4,349,279
+248,540
| +6% | +$16.6M | 3.3% | 13 |
|
|
2021
Q2 | $218M | Buy |
4,100,739
+279,000
| +7% | +$14.8M | 2.38% | 17 |
|
|
2021
Q1 | $166M | Hold |
3,821,739
| – | – | 1.91% | 19 |
|
|
2020
Q4 | $199M | Hold |
3,821,739
| – | – | 2.15% | 18 |
|
|
2020
Q3 | $125M | Hold |
3,821,739
| – | – | 1.66% | 19 |
|
|
2020
Q2 | $184M | Buy |
+3,821,739
| New | +$184M | 2.86% | 15 |
|